Epoxyeicosatrienoic acid analogs and vascular function

Current Medicinal Chemistry

Volumn 17, Issue 12, 2010, Pages 1181-1190

  Sudhahar, V ^a   Shaw, S ^a   Imig, J D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Agonist and antagonist; Analogs; Cardiovascular; Endothelium derived hyperpolarizing factor; Epoxyeicosatrienoic acids; Inflammation

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 11 NONYLOXY UNDEC 8(Z) EONIC ACID; 11,12 EPOXY 5,8,14 ICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 EPOXY 8,11,14 ICOSATRIENOIC ACID; 8,9 EPOXYICOSATRIENOIC ACID; ACETYLCHOLINE; ARACHIDIC ACID; BIMAKALIM; BRADYKININ; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN D; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; EPOXYICOSATRIENOIC ACID; EPOXYICOSATRIENOIC ACID DERIVATIVE; I KAPPA B; I KAPPA B KINASE; ILOPROST; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; METHACHOLINE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ICOSANOID;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CARDIOVASCULAR EFFECT; CELL MIGRATION; CELL PROLIFERATION; DRUG SYNTHESIS; HUMAN; INFLAMMATION; NONHUMAN; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR FUNCTION; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; EICOSANOIDS; HUMANS;

EID: 77950679870     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790827843     Document Type: Review

References (85)

1. Larsen, BT.; Miura, H.; Hatoum, O.A.; Campbell, W.B.; Hammock, B.D.; Zeldin, D.C.; Falck, J.R.; Gutterman, D.D. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H491-9.
2. Zeldin, D.C. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem., 2001, 276, 36059-36062 (Pubitemid 37384204)
3. Daikh, B.E.; Lasker, J.M.; Raucy, J.L.; Koop, D.R. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther., 1994, 271, 1427-1433
4. Zeldin, D.C.; Plitman, J.D.; Kobayashi, J.; Miller, R.F.; Snapper, J.R.; Falck, J.R.; Szarek, J.L.; Philpot, R.M.; Capdevila, J.H. The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance. J. Clin. Invest., 1995, 95, 2150-2160
5. Zou, A.P.; Fleming, J.T.; Falck, J.R.; Jacobs, E.R.; Gebremedhin, D.; Harder, D.R.; Roman, R.J. Stereospecific effects of epoxyeicosatrienoic acids on renal vascular tone and K(+)-channel activity. Am. J. Physiol., 1996, 270, F822-32.
6. Falck, J.R.; Krishna, U.M.; Reddy, Y.K.; Kumar, P.S.; Reddy, K.M.; Hittner, S.B.; Deeter, C.; Sharma, K.K.; Gauthier, K.M.; Campbell, W.B. Comparison of vasodilatory properties of 14,15-EET analogs: structural requirements for dilation. Am. J Physiol. Heart Circ. Physiol., 2003, 284, H337-49.
7. Campbell, W.B.; Gebremedhin, D.; Pratt, P.F.; Harder, D.R. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ. Res., 1996, 78, 415-423
8. Karara, A.; Dishman, E.; Falck, J.R.; Capdevila, J.H. Endogenous epoxyeicosatrienoyl-phospholipids. A novel class of cellular glycerolipids containing epoxidized arachidonate moieties. J. Biol. Chem., 1991, 266, 7561-7569
9. Chen, J.; Capdevila, J.H.; Zeldin, D.C.; Rosenberg, R.L. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol. Pharmacol., 1999, 55, 288-295 (Pubitemid 29076025)
10. Richieri, G.V.; Ogata, R.T.; Zimmerman, A.W.; Veerkamp, J.H.; Kleinfeld, A.M. Fatty acid binding proteins from different tissues show distinct patterns of fatty acid interactions. Biochemistry, 2000, 39, 7197-7204
11. Luxon, B.A.; Milliano, M.T. Cytoplasmic transport of fatty acids in rat enterocytes: role of binding to fatty acid-binding protein. Am. J. Physiol., 1999, 277, G361-6.
12. Widstrom, R.L.; Norris, A.W.; Van Der Veer, J.; Spector, A.A. Fatty acid-binding proteins inhibit hydration of epoxyeicosatrienoic acids by soluble epoxide hydrolase. Biochemistry, 2003, 42, 11762-11767
13. Fang, X.; Kaduce, T.L.; Weintraub, N.L.; VanRollins, M.; Spector, A.A. Functional implications of a newly characterized pathway of 11,12- epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ. Res., 1996, 79, 784-793
14. Fang, X.; Kaduce, T.L.; Weintraub, N.L.; Harmon, S.; Teesch, L.M.; Morisseau, C.; Thompson, D.A.; Hammock, B.D.; Spector, A.A. Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. J. Biol. Chem., 2001, 276, 14867-14874 (Pubitemid 37373365)
15. Newman, J.W.; Morisseau, C.; Hammock, B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res., 2005, 44, 1-51.
16. Yu, Z.; Davis, B.B.; Morisseau, C.; Hammock, B.D.; Olson, J.L.; Kroetz, D.L.; Weiss, R.H. Vascular localization of soluble epoxide hydrolase in the human kidney. Am. J. Physiol. Renal Physiol., 2004, 286, F720-6.
17. Imig, J.D. Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc. Drug Rev., 2006, 24, 169-188 (Pubitemid 46696923)
18. Zeldin, D.C.; DuBois, R.N.; Falck, J.R.; Capdevila, J.H. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch. Biochem. Biophys., 1995, 322, 76-86.
19. Zeldin, D.C.; Moomaw, C.R.; Jesse, N.; Tomer, K.B.; Beetham, J.; Hammock, B.D.; Wu, S. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch. Biochem. Biophys., 1996, 330, 87-96. (Pubitemid 26166628)
20. Zhang, W.; Otsuka, T.; Sugo, N.; Ardeshiri, A.; Alhadid, Y.K.; Iliff, J.J.; DeBarber, A.E.; Koop, D.R.; Alkayed, N.J. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. Stroke, 2008, 39, 2073-2078
21. Zeldin, D.C.; Kobayashi, J.; Falck, J.R.; Winder, B.S.; Hammock, B.D.; Snapper, J.R.; Capdevila, J.H. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J. Biol. Chem., 1993, 268, 6402-6407 (Pubitemid 23099336)
22. Fang, X.; Weintraub, N.L.; McCaw, R.B.; Hu, S.; Harmon, S.D.; Rice, J.B.; Hammock, B.D.; Spector, A.A. Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, H2412-20.
23. Oltman, C.L.; Weintraub, N.L.; VanRollins, M.; Dellsperger, K.C. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ. Res., 1998, 83, 932-939
24. Campbell, W.B.; Deeter, C.; Gauthier, K.M.; Ingraham, R.H.; Falck, J.R.; Li, P.L. 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of K(Ca) channels. Am. J. Physiol. Heart Circ. Physiol., 2002, 282, H1656-64.
25. Imig, J.D.; Navar, L.G.; Roman, R.J.; Reddy, K.K.; Falck, J.R. Actions of epoxygenase metabolites on the preglomerular vasculature. J. Am. Soc. Nephrol., 1996, 7, 2364-2370
26. Sacerdoti, D.; Bolognesi, M.; Di Pascoli, M.; Gatta, A.; McGiff, J.C.; Schwartzman, M.L.; Abraham, N.G. Rat mesenteric arterial dilator response to 11,12-epoxyeicosatrienoic acid is mediated by activating heme oxygenase. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H1999-2002.
27. Dimitropoulou, C.; West, L.; Field, M.B.; White, R.E.; Reddy, L.M.; Falck, J.R.; Imig, J.D. Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins Other Lipid Mediat., 2007, 83, 50-61.
28. Hercule, H.C.; Schunck, W.H.; Gross, V.; Seringer, J.; Leung, F.P.; Weldon, S.M.; da Costa Goncalves Ach.; Huang, Y.; Luft, F.C.; Gollasch, M. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol., 2009, 29, 54-60.
29. Cheng, M.K.; Doumad, A.B.; Jiang, H.; Falck, J.R.; McGiff, J.C.; Carroll, M.A. Epoxyeicosatrienoic acids mediate adenosineinduced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors. Br. J. Pharmacol., 2004, 141, 441-448
30. Ellis, E.F.; Police, R.J.; Yancey, L.; McKinney, J.S.; Amruthesh, S.C. Dilation of cerebral arterioles by cytochrome P-450 metabolites of arachidonic acid. Am. J. Physiol., 1990, 259, H1171-7.
31. Gebremedhin, D.; Ma, Y.H.; Falck, J.R.; Roman, R.J.; VanRollins, M.; Harder, D.R. Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle. Am. J. Physiol., 1992, 263, H519-25.
32. Gauthier, K.M.; Deeter, C.; Krishna, U.M.; Reddy, Y.K.; Bondlela, M.; Falck, J.R.; Campbell, W.B. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ. Res., 2002, 90, 1028-1036
33. Gauthier, K.M.; Jagadeesh, S.G.; Falck, J.R.; Campbell, W.B. 14,15-epoxyeicosa-5(Z)-enoic-mSI: a 14,15- and 5,6-EET antagonist in bovine coronary arteries. Hypertension, 2003, 42, 555-561
34. Imig, J.D.; Dimitropoulou, C.; Reddy, D.S.; White, R.E.; Falck, J.R. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. Microcirculation, 2008, 15, 137-150
35. Imig, J.D.; Inscho, E.W.; Deichmann, P.C.; Reddy, K.M.; Falck, J.R. Afferent arteriolar vasodilation to the sulfonimide analog of 11, 12-epoxyeicosatrienoic acid involves protein kinase A. Hypertension, 1999, 33: 408-413
36. Carroll, M.A.; Doumad, A.B.; Li, J.; Cheng, M.K.; Falck, J.R.; McGiff, J.C. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am. J. Physiol. Renal Physiol., 2006, 291, F155-61.
37. Weston, A.H.; Félétou, M.; Vanhoutte, P.M.; Falck, J.R.; Campbell, W.B.; Edwards, G. Bradykinin-induced, endothelium-dependent responses in porcine coronary arteries: involvement of potassium channel activation and epoxyeicosatrienoic acids. Br. J. Pharmacol., 2005, 145, 775-784 (Pubitemid 41076284)
38. Vriens, J.; Owsianik, G.; Fisslthaler, B.; Suzuki, M.; Janssens, A.; Voets, T.; Morisseau, C.; Hammock, B.D.; Fleming, I.; Busse, R.; Nilius, B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ. Res., 2005, 97, 908-915 (Pubitemid 41552676)
39. Kessler, P.; Popp, R.; Busse, R.; Schini-Kerth, V.B. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation, 1999, 99, 1878-1884
40. Collins, T.; Read, M.A.; Neish, A.S.; Whitley, M.Z.; Thanos, D.; Maniatis, T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J., 1995, 9, 899-909.
41. Node, K.; Huo, Y.; Ruan, X.; Yang, B.; Spiecker, M.; Ley, K.; Zeldin, D.C.; Liao, J.K. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science, 1999, 285, 276-279
42. Schmelzer, K.R.; Kubala, L.; Newman, J.W.; Kim, I.H.; Eiserich, J.P.; Hammock, B.D. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 9772-9777
43. Falck, J.R.; Reddy, L.M.; Reddy, Y.K.; Bondlela, M.; Krishna, U.M.; Ji, Y.; Sun, J.; Liao, J.K. 11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression. Bioorg. Med. Chem. Lett., 2003, 13, 4011-4014
44. Liu, Y.; Zhang, Y.; Schmelzer, K.; Lee, T.S.; Fang, X.; Zhu, Y.; Spector, A.A.; Gill, S.; Morisseau, C.; Hammock, B.D.; Shyy, J.Y. The antiinflammatory effect of laminar flow: the role of PPAR-gamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 16747-16752
45. Potente, M.; Michaelis, U.R.; Fisslthaler, B.; Busse, R.; Fleming, I. Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and upregulation of cyclin D1. J. Biol. Chem., 2002, 277, 15671-15676 (Pubitemid 34967840)
46. Potente, M.; Fisslthaler, B.; Busse, R.; Fleming, I. 11,12- Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem., 2003, 278, 29619-29625 (Pubitemid 36962345)
47. Yan, G.; Chen, S.; You, B.; Sun, J. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc. Res., 2008, 78, 308-314 (Pubitemid 351556100)
48. Sun, J.; Sui, X.; Bradbury, J.A.; Zeldin, D.C.; Conte, M.S.; Liao, J.K. Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. Circ. Res., 2002, 90, 1020-1027 (Pubitemid 34633869)
49. Davis, B.B.; Thompson, D.A.; Howard, L.L.; Morisseau, C.; Hammock, B.D.; Weiss, R.H. Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U S A., 2002, 99, 2222-2227
50. Yang, S.; Wei, S.; Pozzi, A.; Capdevila, J.H. The arachidonic acid epoxygenase is a component of the signaling mechanisms responsible for VEGF-stimulated angiogenesis. Arch. Biochem. Biophys., 2009, PMID: 194464254, (in press).
51. Pozzi, A.; Macias-Perez, I.; Abair, T.; Wei, S.; Su, Y.; Zent, R.; Falck, J.R.; Capdevila J.H. Characterization of 5,6 - and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J. Biol. Chem., 2005, 280, 27138-27146
52. Fitzpatrick, F.A.; Ennis, M.D.; Baze, M.E.; Wynalda, M.A.; McGee, J.E.; Liggett, W.F. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J. Biol. Chem., 1986, 261, 15334-15338
53. Heizer, M.L.; McKinney, J.S.; Ellis, E.F. 14,15-Epoxyeicosatrienoic acid inhibits platelet aggregation in mouse cerebral arterioles. Stroke, 1991, 22, 1389-1393
54. Krötz, F.; Riexinger, T.; Buerkle, M.A.; Nithipatikom, K.; Gloe, T.; Sohn, H.Y.; Campbell, W.B.; Pohl, U. Membrane-potentialdependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 595-600. (Pubitemid 38326158)
55. Collen, D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb. Haemost., 1980, 43, 77-89. (Pubitemid 10063059)
56. Node, K.; Ruan, X.L.; Dai, J.; Yang, S.X.; Graham, L.; Zeldin, D.C.; Liao, J.K. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J. Biol. Chem., 2001, 276, 15983-15989 (Pubitemid 37391633)
57. Imig, J.D. epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. Renal Physiol., 2005, 289, F496-503.
58. Snyder, G.D.; Krishna, U.M.; Falck, J.R.; Spector, A.A. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1936-42.
59. Spector, A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, 50, S52-56.
60. Corey, E.J.; Niwa, H.; Falck, J.R. Selective epoxidation of Eicosacis-5,8,11,14-Tetraenoic (Arachidonic) acid and Eicosa-cis-8,1,14-Trienoic acid. J. Am. Chem. Soc., 1979, 101, 1586-1587
61. Rosolowsky, M.; Campbell, W.B. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am. J. Physiol., 1993, 264, H327-35.
62. Gauthier, K.M.; Falck, J.R.; Reddy, L.M.; Campbell, W.B. 14,15-EET analogs: characterization of structural requirements for agonist and antagonist activity in bovine coronary arteries. Pharmacol. Res., 2004, 49, 515-524
63. Yang, W.; Holmes, B.B.; Gopal, V.R.; Kishore, R.V.; Sangras, B.; Yi, X.Y.; Falck, J.R.; Campbell, W.B. Characterization of 14,15-epoxyeicosatrienoyl- sulfonamides as 14,15-epoxyeicosatrienoic acid agonists: use for studies of metabolism and ligand binding. J. Pharmacol. Exp. Ther., 2007, 321, 1023-1031
64. Sacerdoti, D.; Bolognesi, M.; Di Pascoli, M.; Gatta, A.; McGiff, J.C.; Schwartzman, M.L. JR.; Spector, A.A. Evidence for a membrane site of action for 14,15-EET on expression of aromatase in vascular smooth muscle. Am. J. Physiol. Heart Circ. Physiol., 2002, 283, H1936-42.
65. Fang, X.; Hu, S.; Xu, B.; Snyder, G.D.; Harmon, S.; Yao, J.; Liu, Y.; Sangras, B.; Falck, J.R.; Weintraub, N.L.; Spector, A.A. 14,15- Dihydroxyeicosatrienoic acid activates peroxisome proliferatoractivated receptor-alpha. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H55-63.
66. Sun, P.; Lin, D.H.; Wang, T.; Babilonia, E.; Wang, Z.; Jin, Y.; Kemp, R.; Nasjletti, A.; Wang, W.H. Low Na intake suppresses expression of CYP2C23 and arachidonic acid-induced inhibition of ENaC. Am. J. Physiol. Renal Physiol., 2006, 291, F1192-1200.
67. Nakagawa, K.; Holla, V.R.; Wei, Y.; Wang, W.H.; Gatica, A.; Wei, S.; Mei, S.; Miller, C.M.; Cha, D.R.; Price, E. Jr.; Zent, R.; Pozzi, A.; Breyer, M.D.; Guan, Y.; Falck, J.R.; Waterman, M.R.; Capdevila, J.H. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest., 2006, 116, 1696-1702. (Pubitemid 43911024)
68. Imig, J.D.; Zhao, X.; Falck, J.R.; Wei, S.; Capdevila, J.H. Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12 - epoxyeicosatrienoic acid. J. Hypertens., 2001, 19, 983-992
69. Imig, J.D.; Falck, J.R. Compositions and methods for the treatment of rnela and cardiovascular disease. US Patent #7,550,617, 2009.
70. Elmarakby, A.A.; Falck, J.R.; Imig, J.D. Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered invivo to the spontaneouly hypertensive rats. FASEB. J., 2008, 22, 479.44. (abstract) http://www.fasebj. org/cgi/content/meeting-abstract/22/1-MeetingAbstracts/479.44
71. Sodhi, K.; Inoue, K.; Gotlinger, K.H.; Canestraro, M.; Vanella, L.; Kim, D.H.; Manthati, V.L.; Koduru, S.R.; Falck, J.R.; Schwarzman, M.L.; Abraham, N.G. Epoxyeicosatrienoic acid agonist rescues metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther., 2009, 331, 906-916
72. Ng, V.Y.; Huang, Y.; Reddy, L.M.; Falck, J.R.; Lin, E.T.; Kroetz, D.L. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab. Dispos., 2007, 35, 1126-1134 (Pubitemid 46956433)
73. Burns, K.D.; Capdevila, J.; Wei, S.; Breyer, M.D, Homma T, Harris RC. Role of cytochrome P-450 epoxygenase metabolites in EGF signaling in renal proximal tubule. Am. J. Physiol., 1995, 269, C831-40.
74. Chen, J.K.; Falck, J.R.; Reddy, K.M.; Capdevila, J.; Harris, R.C. Epoxyeicosatrienoic acids and their sulfonimide derivatives stimulate tyrosine phosphorylation and induce mitogenesis in renal epithelial cells. J. Biol. Chem., 1998, 273, 29254-29261
75. Chen, J.K.; Capdevila, J.; Harris, R.C. Overexpression of C-terminal Src kinase blocks 14, 15-epoxyeicosatrienoic acid-induced tyrosine phosphorylation and mitogenesis. J. Biol. Chem., 2000, 275, 13789-13792
76. Carroll, M.A.; Garcia, M.P.; Falck, J.R.; McGiff, J.C. 5,6-epoxyeicosatrienoic acid, a novel arachidonate metabolite. Mechanism of vasoactivity in the rat. Circ. Res., 1990, 67, 1082-1088
77. Fulton, D.; Falck, J.R.; McGiff, J.C.; Carroll, M.A.; Quilley, J. A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. J. Lipid Res., 1998, 39, 1713-1721 (Pubitemid 28377937)
78. Carroll, M.A.; Balazy, M.; Margiotta, P.; Falck, J.R.; McGiff, J.C. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. J. Biol. Chem., 1993, 268, 12260-12266
79. Yang, W.; Gauthier, K.M.; Reddy, L.M.; Sangras, B.; Sharma, K.K.; Nithipatikom, K.; Falck, J.R.; Campbell, W.B. Stable 5,6-epoxyeicosatrienoic acid analog relaxes coronary arteries through potassium channel activation. Hypertension, 2005, 45, 681-686
80. Archer, S.L.; Gragasin, F.S.; Wu, X.; Wang, S.; McMurtry, S.; Kim, D.; Platonov, M.; Koshal, A.; Hashimoto, K.; Campbell, W.B.; Falck, J.R.; Michelakis, E.D. Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. Circulation, 2003, 107, 769-776
81. Nayeem, M.A.; Poloyac, S.M.; Falck, J.R.; Zeldin, D.C.; Ledent, C.; Ponnoth, D.S.; Ansari, H.R.; Mustafa, S.J. Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice. Am. J. Physiol. Heart Circ. Physiol., 2008, 295, H2068-78.
82. Gross, G.J.; Gauthier, K.M.; Moore, J.; Campbell, W.B.; Falck, J.R.; Nithipatikom, K. Evidence for role of epoxyeicosatrienoic acids in mediating ischemic preconditioning and postconditioning in dog. Am. J. Physiol. Heart Circ. Physiol., 2009, 297, H47-52.
83. Jin, L.; Foss, C.E.; Zhao, X.; Mills, T.M.; Wang, M.H.; McCluskey, L.P.; Yaddanapud, G.S.; Falck, J.R.; Imig, J.D.; Webb, R.C. Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB J., 2006, 20, 539-541
84. Chen, Y.; Falck, J.R.; Tuniki, V.R.; Campbell, W.B. 20-125Ido-14,15- epoxyeicosa-5(Z)-enoic acid: a high affinity radioligand used to charaterize the epoxyeicosatrienoic acid antagonist binding site. J. Pharmacol. Exp. Ther., 2009, 331, 1137-1145
85. Falck, J.R.; Kodela, R.; Manne, R.; Atcha, R.; Puli, N.; Dubasi, N.; Manthati, V.L.; Capdevila, J.H.; Yi, X.Y.; Goldman, D.H.; Morisseau, C.; Hammock, B.D.; Campbell, W.B. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxide hydrolase inhibition. J. Med. Chem., 2009, 52, 5069-5075